News & Events
Disc Medicine to Present at Citi's 15th Annual BioPharma Virtual Conference
Cambridge, Mass. – September 8, 2020 – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that John Quisel, J.D., Ph.D., Chief Executive Officer of Disc Medicine, will present at Citi’s 15th Annual BioPharma Virtual Conference today, Tuesday, September 8, 2020 at 2:20pm ET.
About Disc Medicine
Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. Focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is developing a portfolio of first-in-class therapeutic candidates to transform the treatment of hematologic diseases. For more information, visit www.discmedicine.com.
Media Contact:
Arleen Goldenberg
Verge Scientific Communications
202.930.4762
More News
Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update
Company on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) under accelerated approval pathway in October 2025, supported by successful...
read more
Disc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in October 2025
WATERTOWN, Mass., July 21, 2025 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...
read more
Disc Medicine Appoints Nadim Ahmed to its Board of Directors
WATERTOWN, Mass., July 14, 2025 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...
read more